Sanofi SA Announces Results of New GetGoal-L Sub-analysis of Lyxumia


Tuesday, 24 Sep 2013 06:16am EDT 

Sanofi SA announced new GetGoal-L sub-analysis results showing that reductions in HbA1c with the Company's Lyxumia (lixisenatide), when added to basal insulin, were greatest in patients with type 2 diabetes who had well-controlled baseline fasting plasma glucose (FPG). These findings are consistent with the efficacy profile of Lyxumia, which shows a clinical and statistically reduction in HbA1c across different patient populations. 

Company Quote

74.1
0.62 +0.84%
17 Dec 2014